NovellusDx Raises $10M in Private Financing Round | GenomeWeb

NEW YORK (GenomeWeb) – Israeli cancer diagnostics developer NovellusDx has raised $10 million in a private financing round.

The round, led by life sciences holding company IntraCure and life sciences venture capital financier Pontifax, includes an option for an additional $10 million investment, the company said in a statement.

Founded in 2012, the firm has developed technology to monitor signaling pathways and identify driver mutations in different kinds of cancer, and monitor the effects of targeted therapies on those mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.